82. Eur J Cancer. 2018 May;94:199-205. doi: 10.1016/j.ejca.2018.02.018. Epub 2018 Mar21.Outcomes of single versus double hormone receptor-positive breast cancer. AGEICAM/9906 sub-study.Ethier JL(1), Ocaña A(2), Rodríguez Lescure A(3), Ruíz A(4), Alba E(5), CalvoL(6), Ruíz-Borrego M(7), Santaballa A(8), Rodríguez CA(9), Crespo C(10), RamosM(11), Gracia Marco J(12), Lluch A(13), Álvarez I(14), Casas M(15), Sánchez-AragóM(15), Carrasco E(15), Caballero R(15), Amir E(16), Martin M(17).Author information: (1)Department of Medical Oncology, Kingston Health Sciences Centre, Queen'sUniversity, Kingston, Ontario, Canada.(2)Complejo Hospitalario de Albacete, Albacete, Spain; GEICAM (Spanish BreastCancer Group), Spain; Centro de Investigación Biomédica en Red de Oncología,CIBERONC-ISCIII, Spain.(3)GEICAM (Spanish Breast Cancer Group), Spain; Hospital Universitario de Elche, Elche, Spain.(4)GEICAM (Spanish Breast Cancer Group), Spain; Instituto Valenciano deOncología, Valencia, Spain.(5)GEICAM (Spanish Breast Cancer Group), Spain; Hospital Virgen de La Victoria,Málaga, Spain; Centro de Investigación Biomédica en Red de Oncología,CIBERONC-ISCIII, Spain.(6)GEICAM (Spanish Breast Cancer Group), Spain; Complejo HospitalarioUniversitario A Coruña, A Coruña, Spain.(7)GEICAM (Spanish Breast Cancer Group), Spain; Hospital Univ. Virgen Del Rocío, Sevilla, Spain.(8)GEICAM (Spanish Breast Cancer Group), Spain; Hospital Universitario La Fe,Valencia, Spain.(9)GEICAM (Spanish Breast Cancer Group), Spain; Hospital Clínico Universitario deSalamanca, Salamanca (IBSAL), Spain.(10)GEICAM (Spanish Breast Cancer Group), Spain; Hospital Ramón y Cajal, Madrid, Spain.(11)GEICAM (Spanish Breast Cancer Group), Spain; Centro Oncológico de Galicia, A Coruña, Spain.(12)GEICAM (Spanish Breast Cancer Group), Spain; Hospital de Cabueñes, Gijón,Spain.(13)GEICAM (Spanish Breast Cancer Group), Spain; Centro de InvestigaciónBiomédica en Red de Oncología, CIBERONC-ISCIII, Spain; Hospital ClínicoUniversitario de Valencia, Biomedical Research Institute INCLIVA, University ofValencia, Valencia, Spain.(14)GEICAM (Spanish Breast Cancer Group), Spain; Hospital de Donostia, SanSebastián, Spain.(15)GEICAM (Spanish Breast Cancer Group), Spain.(16)Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre,Toronto, Canada.(17)GEICAM (Spanish Breast Cancer Group), Spain; Centro de InvestigaciónBiomédica en Red de Oncología, CIBERONC-ISCIII, Spain; Instituto de InvestigaciónSanitaria Gregorio Marañón, Madrid, Spain. Electronic address:mmartin@geicam.org.BACKGROUND: Retrospective data suggest better outcomes for patients with doublehormonal receptor (oestrogen [ER] and progesterone receptor [PgR])-positive(dHR+) early breast cancer, compared with single hormonal receptor-positive,sHR+, (ER+/PgR- or ER-/PgR+) disease. Here, we evaluate the classificationaccording to intrinsic subtypes and clinical outcomes of sHR+ versus dHR+ inHER2-negative breast cancer patients enrolled in GEICAM/9906 study (NCT00129922).METHODS: Archival tumours were retrieved retrospectively for the analysis of ER, PgR and HER2 status and classified into intrinsic subtypes using the PAM50 geneexpression assay. Disease-free survival (DFS) and overall survival (OS) wereexplored using a Cox proportional hazard analysis.RESULTS: Data on intrinsic subtypes were available in 571 (50%) patients with ER+and/or PR+, and HER2-negative primary tumours. The incidence of luminal A andluminal B subtypes were 52%/36% in dHR+ tumours (ER+/PgR+), and 15%/58% inER+/PgR-tumours. ER-/PgR+ tumours were mainly luminal A (52%). Compared withER+/PgR+ patients, DFS was similar in ER-/PgR+ (hazard ratio [HR] 1.15, 95%confidence interval [CI] 0.57-2.34, p = 0.70) but worse in ER+/PgR- patients (HR 1.60, 95% CI 1.12-2.28, p < 0.01). Similar results were observed for OS (HR 1.50,p = 0.30 and HR 1.86, p < 0.01, respectively).CONCLUSIONS: The ER+/PgR- group is characterised by higher proliferation andworse outcomes. In spite of the ER-/PgR+ subgroup resembles ER+/PgR+ disease interms of molecular subtypes and outcomes, the small number of patients in thissubgroup prevents from drawing any conclusions.TRIAL REGISTRATION: EudraCT: 2005-003108-12 (retrospectively registered28/06/2005). CLINICALTRIALS.GOV IDENTIFIER: NCT00129922 (retrospectively registered 10/08/2005).Copyright © 2018 Elsevier Ltd. All rights reserved.DOI: 10.1016/j.ejca.2018.02.018 PMID: 29573665 